936PDA phase II study of durvalumab, a PD-L1 inhibitor and olaparib in recurrent ovarian cancer (OvCa). (23rd October 2018) - Lee, J-M; Annunziata, C M; Houston, N; Kohn, E C; Lipkowitz, S; Minasian, L; Nichols, E; Trepel, J; Trewhitt, K; Zia, F; Zimmer, A D S